Physician profile
Nathaniel Doe
NPI 1275504094
$9,111.63
in general payments reported to CMS, 2019-2025
35 companies · $1,593 in 2025
The $1,593 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,344 · 2020: $1,025 · 2021: $1,125 · 2022: $1,149 · 2023: $1,177 · 2024: $1,698 · 2025: $1,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,393 · Education: $75.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,392.79 |
| Education | $75.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,279.78 | 2019-2025 | Tavneos, Krystexxa, Uplizna |
| Astrazeneca Pharmaceuticals Lp | $1,090.94 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $1,032.00 | 2019-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $882.62 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $811.89 | 2019-2025 | Jynarque, Voyxact |
| Akebia Therapeutics INC | $372.33 | 2019-2025 | Auryxia, Vafseo |
| Mallinckrodt Hospital Products INC. | $371.25 | 2020-2025 | Terlivaz, Acthar |
| Novartis Pharmaceuticals Corporation | $360.07 | 2019-2025 | |
| Daiichi Sankyo INC. | $341.88 | 2019-2022 | |
| Glaxosmithkline, LLC. | $304.81 | 2022-2024 | Jesduvroq, Benlysta |
| Travere Therapeutics, INC. | $292.16 | 2022-2025 | |
| Horizon Therapeutics Plc | $288.07 | 2021-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $199.12 | 2019-2023 | Ultomiris |
| Fresenius USA Marketing, INC. | $184.92 | 2019-2025 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.39 | 2024-2025 | Jardiance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $151.97 | 2024-2025 | Ibsrela |
| Bard Peripheral Vascular, INC. | $148.71 | 2019 | |
| Aurinia Pharma U.S., INC. | $114.04 | 2021-2023 | Lupkynis |
| Shield Therapeutics INC | $88.05 | 2024-2025 | |
| Genzyme Corporation | $85.80 | 2019-2023 | |
| Novo Nordisk INC | $85.51 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Opko Pharmaceuticals, LLC | $72.07 | 2024 | Rayaldee |
| Arbor Pharmaceuticals, INC. | $63.88 | 2021 | |
| Calliditas Therapeutics US INC. | $45.67 | 2023-2024 | Tarpeyo |
| Scpharmaceuticals INC. | $38.40 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $36.94 | 2019 | |
| Lundbeck LLC | $34.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.06 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $25.37 | 2024 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $25.07 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $24.06 | 2021 | |
| Apellis Pharmaceuticals, INC. | $21.82 | 2025 | Empaveli |
| Lilly USA, LLC | $16.56 | 2024 | Jardiance |
| Abbott Laboratories | $16.41 | 2019 | |
| Mallinckrodt Enterprises LLC | $14.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Doe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.